Molterfin (Buprenorphine)

Buprenorphine acts as a partial agonist at the μ‑opioid receptor, delivering pain relief while limiting maximal respiratory depression. It also antagonizes κ‑opioid receptors, which contributes to its ceiling effect on certain side effects and may improve mood stability during opioid substitution therapy.

The specific dose of Molterfin is determined by the prescribing clinician based on the individual patient's condition, prior opioid exposure, and response to therapy. Healthcare professionals tailor the regimen to achieve adequate pain control or withdrawal management while minimizing adverse effects.

Safety data for buprenorphine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and discuss options with the patient. If treatment is deemed necessary, it should be managed by a qualified healthcare provider familiar with maternal‑fetal considerations.

To request Molterfin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with methadone, another opioid used for dependence, buprenorphine (Molterfin) has a higher receptor affinity and a ceiling effect for respiratory depression, which can improve safety. Methadone is a full agonist and may cause more pronounced respiratory depression, whereas buprenorphine often requires less intensive monitoring.

Molterfin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Molterfin is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or dissolved unless specifically instructed by a healthcare professional.

The most serious risks include respiratory depression, severe hypotension, and allergic reactions such as anaphylaxis. Patients should be monitored for signs of breathing difficulty, sudden drops in blood pressure, or rash and swelling, and medical attention should be sought immediately if these occur.

Molterfin is contraindicated in individuals with known hypersensitivity to buprenorphine or any of its excipients, in patients with severe respiratory insufficiency, and in those receiving prohibited concomitant medications such as certain CNS depressants. Caution is also advised for patients with significant hepatic impairment.